Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices [6] (multiple letters)

Journal of Allergy and Clinical Immunology

Volumn 113, Issue 3, 2004, Pages 568-569

  Metcalfe, Scott ^a   Moodie, Peter ^a   Nelson, Harold S ^b   Chapman, Kenneth R ^c   Pyke, Stephen D ^d   Johnson, Malcolm ^d   Pritchard, John N ^d  

^a Pharmaceutical Management Agency   (New Zealand)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL;

ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LETTER; MATHEMATICAL COMPUTING; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME;

EID: 1542511358     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.12.005     Document Type: Letter

References (3)

1. HS Nelson KR Chapman SD Pyke M Johnson JN Pritchard Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers J Allergy Clin Immunol 112 2003 29 36
2. HT Davies IK Crombie M Tavakoli When can odds ratios mislead? BMJ 316 1998 989 991
3. S Shrewsbury S Pyke M Britton Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) BMJ 320 2000 1368 1373